Date: 2014-08-21
Type of information: R&D agreement
Compound: fully humanized antibodies using Antitope’s Composite Human Antibody™ technology including a humanized anti-LRG1 antibody
Company: Antitope, an Abzena\'s subsidiary (UK) University College London (UCL) (UK)
Therapeutic area: Ophtalmological diseases
Type agreement: R&D licensing
Action mechanism:
Disease: ophtalmological diseases
Details: * On August 21, 2014, Antitope, an Abzena company that provides services and technologies to enable the development of better biopharmaceuticals, and University College London (“UCL”), have announcec that they will collaborate to humanize an anti-LRG1 antibody as part of a MRC-funded translational research and product development programme being undertaken by the UCL Institute of Ophthalmology. The collaboration is supported by UCL Business PLC (UCLB), UCL’s wholly owned technology transfer company, which provided initial Proof of Concept funding and holds the patents to the LRG1 technologies. LRG1 (leucine-rich alpha-2-glycoprotein 1) was identified by researchers at UCL to promote angiogenesis. Antitope will produce a range of fully humanized antibodies using its Composite Human Antibody™ technology that are designed to bind to and inhibit the function of LRG1. UCL will select a lead antibody for further evaluation as a potential therapeutic product for the treatment of age-related macular degeneration (AMD). UCLB is continuing to support development of this technology and is currently seeking commercial partners to take it to market. No commercial terms are disclosed.
Financial terms:
Latest news:
